AGENUS INC (AGEN)       2.61  +0.06 (+2.35%)

2.61  +0.06 (+2.35%)

US00847G7051 - Common Stock - After market: 2.67 +0.06 (+2.3%)

News Image
6 days ago - Agenus Inc.

Agenus to Participate in February Investor Conferences

LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting...

News Image
9 days ago - Agenus Inc.

Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Overall response rate (ORR) of 23% and disease control rate (DCR) of 76% in expanded cohort of 70 heavily pre-treated patients; data suggest superior...

News Image
a month ago - Agenus Inc.

Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI

LEXINGTON, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics...

News Image
a month ago - InvestorPlace

7 Hot Stocks to Book Profits In Before 2023

With major macroeconomic headwinds appearing on the horizon, it’s time for investors to consider the hot stocks to book profits in.

News Image
2 months ago - The Motley Fool

Why Shares of Agenus Rose 12.5% on Friday

Agenus presented data this week on a combination therapy.

News Image
3 months ago - Agenus Inc.

Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma

Overall response rate (ORR) of 46% and disease control rate (DCR) of 69% in heavily pre-treated patients who have received a median of 3 prior lines of...

News Image
3 months ago - Agenus Inc.

Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference

LEXINGTON, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and...

News Image
3 months ago - Seeking Alpha

AGEN stock spikes on Phase 1 data for cancer candidates (NASDAQ:AGEN)

Immuno-oncology company Agenus Inc. (AGEN) added ~11% on Monday after announcing data from a Phase 1 study for cancer candidates botensilimab and balstilimab in patients with...

News Image
3 months ago - Agenus Inc.

Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers

Overall response rates ranged from 22% in microsatellite stable colorectal cancer (MSS-CRC) to 60% in PD-(L)1 refractory non-small cell lung cancer...

News Image
3 months ago - The Motley Fool

Agenus (AGEN) Q3 2022 Earnings Call Transcript

AGEN earnings call for the period ending September 30, 2022.

News Image
3 months ago - Agenus Inc.

Agenus Provides Corporate Update and Third Quarter 2022 Financial Report

Company to present expanded data from Phase 1 study of botensilimab (Fc-enhanced anti-CTLA-4) at plenary session of the Society for Immunotherapy of Cancer...

News Image
3 months ago - Agenus Inc.

Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report

Conference Call on Tuesday, November 8, 2022, at 8:30 a.m. ETCompany to host “The Road Taken” R&D Event in Boston on November 12 from 2p.m. – 5p.m. ET...

News Image
4 months ago - Agenus Inc.

GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial

Data show overall vaccine efficacy of 82.6% against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above, with consistent high...